High Quality and Stable Creatine Kinase, MB Diagnostic Enzyme

Name: High Quality and Stable Creatine Kinase, MB Diagnostic Enzyme
Brand: Hubei New Desheng Material Technology Co., Ltd
SKU: 2236639545

Hubei, ChinaHubei New Desheng Material Technology Co., Ltd

Negotiable

10 ku

Product profile

Customization

Available

CAS No.

9001-15-4

Formula

Model NO.

Creatine Kinase, MB

EINECS

Ec:2.7.3.2

Classification

Enzyme Preparation

Grade

Specific Usage

For Biological Purpose

Content

Standard

Usage

Laboratory Reagents, Analytical Reagents, Diagnostic Reagents

Source

Composition

Habit Appellation

Enzyme Preparation

Application

Scientific Research, Health

Property

Biochemical Reagent

Storage

Low Temperature Storage

Use to

in Vitro Diagnostic Kit

Manufactor

Hubei New Desheng Material Technology Co., Ltd

Dosage Form

White Freeze-Dried Powder

Molecular Weight

About 110kda

Transport Package

Refrigerated Transport

Specification

10ku/bottle

Trademark

DeSheng

Origin

Ezhou City, Hubei Province, China

Production Capacity

50g Per Month

Key features

High Specific Activity: Enzyme activity reaches 2000 U/mg for efficient catalytic performance.

Myocardial Injury Marker: CK-MB is a specific indicator for diagnosing acute myocardial infarction.

Gene Recombination Source: Produced via gene recombination expression for consistent quality.

Custom OEM/ODM Service: Supports customization from samples for specific diagnostic needs.

Trinder Reaction Compatible: Optimized for use in Trinder reaction-based in vitro diagnostic kits.

Professional Manufacturer: Produced by Hubei New Desheng with advanced R&D and production.

Company profile

Importers and ExportersPatents AwardedExhibition Experience

Hubei New Desheng Material Technology Co., Ltd

Hubei, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Customization from Samples CertifiedExport Year: 7 Years CertifiedNearest Port: Shanghai PortAverage Response Time: ≤7.01h

AI-Powered supplier vetting

SummaryThe supplier is a combined manufacturing and trading enterprise with chemical, synthetic-material, medical-device, and related product activities. It reports two production lines, specified annual capacities for several products, finished-product inspection instructions, inventory capability, and an off-peak lead time within 15 working days. Service processes for corrective and preventive actions and customer complaints are documented and followed. R&D personnel provide technical support, with design and verification records available for audit, but no SDK is available. The supplier provides OEM services for well-known brands and can customize from samples. Limitations include no valid manufacturing-capacity contract with related subcontractors, no overseas warehouse, showroom, agent, or branch, and no stated overseas service countries. No explicit certification holdings or customer case details are provided.

Supplier typeThe supplier’s stated scope covers manufacturing of basic chemical raw materials, synthetic and bio-based materials, special chemical products, sealing fillers, engineering plastics, and Category I and Category II medical-device sales. It is identified as a combined company rather than an offshore company, indicating a mixed manufacturing and commercial operating model.

After-Sales capabilityThe supplier has documented and followed procedures for corrective and preventive actions and customer complaints, and technology engineers provide technical support for production and after-sales service. However, it reports no overseas agents or branches, no overseas warehouse or showroom, and zero stated countries for overseas services, limiting evidence of local international support.

R&D capabilityR&D engineers are responsible for R&D and technical support, and relevant design input, output, review, verification, and validation documents are available for audit. The supplier reports software-instrument capability using MestReNova, but no SDK is available, so the evidence supports established R&D activity rather than full software-development integration capability.

Production capacityThe supplier operates two production lines and reports defined annual capacities, including 600 tons of serum separation gel, 500 tons of tris base, 30 tons of dipotassium ethylenediaminetetraacetate, 20 tons of tripotassium EDTA, and 0.6 tons of lithium heparin. It also reports inventory capability, standardized finished-product inspection instructions, and an off-peak lead time within 15 working days; however, it lacks a valid manufacturing-capacity contract with related subcontractors.

Customization capabilityThe supplier explicitly offers design customization from samples and reports OEM services for well-known brands. Its quality-control information also states that own-brand product quality-control capability is present, although the specific designation is recorded as “DS.”